Skip to main content
BROOKS LABORATORIES LIMITED logo

BROOKS LABORATORIES LIMITED — Investor Relations & Filings

Listed
Ticker · BROOKS ISIN · INE650L01011 LEI · 984500FY0879C7971B73 BSE.NS Manufacturing
Open in API
Filings indexed 503 across all filing types
Latest filing 2026-06-20 Capital/Financing Update
Country IN India
Listing BSE.NS BROOKS · 2 venues

About BROOKS LABORATORIES LIMITED

https://www.brookslabs.net/

Brooks Laboratories Limited is a pharmaceutical manufacturing enterprise specializing in Contract Research and Manufacturing Services (CRAMS). The company focuses on the production of a diverse range of pharmaceutical formulations, including beta-lactam and non-beta-lactam products. Its portfolio encompasses various dosage forms such as dry powder injections, liquid injections, tablets, and capsules. Key therapeutic segments served include antibiotics, cardiovascular, gastrointestinal, and pain management. The company operates advanced manufacturing facilities designed to meet international quality standards, providing integrated solutions from formulation development to commercial-scale production. Brooks Laboratories emphasizes quality control and regulatory compliance to support its domestic and international client base.

Recent filings

Filing Released Lang Actions
Updates
Capital/Financing Update Classification · 95% confidence The document is a notice submitted to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details a corporate action: the partial sale of equity shares held in a subsidiary company. It includes specifics about the share sale transaction such as number of shares, sale price, percentages before and after, and board meeting times. The document is an update provided to regulators about a financial transaction impacting shareholding. It is clearly not a full financial report, earnings release, call transcript, or annual report but rather a corporate announcement of a capital transaction. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (6002 characters) and form confirm this is the announcement itself, not just a report publication notice or certification. Therefore, the correct classification is CAP with high confidence.
2026-06-20 English
With reference to corporate announcement titled "Partial Sale of Equity Shares held in Brooks Steriscience Limited" submitted by the Company on 19th June 2026, we wish to inform you that ....
Capital/Financing Update Classification · 95% confidence The document is a regulatory announcement submitted under SEBI (LODR) Regulations, 2015. It details the approval of the company's Board of Directors for a partial sale of equity shares held in a subsidiary entity, Brooks Steriscience Limited. It provides specifics about the transaction such as number of shares sold, price per share, percentage of shareholding before and after sale, and board meeting timings. The document references compliance with SEBI regulations and provides corporate announcement details, indicating it is a corporate action disclosure. There are no financial statements, nor comprehensive management discussion or annual reporting content. The document is not an earnings release or audit report; it clearly fits as a Capital/Financing Update (CAP) since it involves a significant equity transaction and divestment announcement governed by regulatory disclosure requirements under SEBI norms.
2026-06-20 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) reporting the Board of Directors' approval for the sale of equity shares in a subsidiary company. It includes detailed information such as number of shares sold, consideration amount, shareholding percentages before and after the transaction, and regulatory references like SEBI Listing Regulations. This is characteristic of a capital or financing update specifically about a share sale (partial divestment). The document is relatively short (about 4,060 characters) and focuses on the sale transaction instead of any financial results or detailed financial statements. Therefore, this document best fits the 'Capital/Financing Update (CAP)' category, as it announces a significant financing-related transaction involving equity shares.
2026-06-19 English
We hereby inform that the Company at its board meeting held today i.e 19th June 2026 has approved sale of 51,220 equity shares held by the Company in Brooks Steriscience Limited to Steriscience ....
Capital/Financing Update Classification · 95% confidence The document is an official communication from Brooks Laboratories Limited informing stock exchanges about the sale of equity shares held in another company, Brooks Steriscience Limited. It references compliance with SEBI Listing Regulations and provides detailed transaction information such as quantity of shares sold, shareholding percentages before and after disposal, and transaction approval date. This is clearly an announcement regarding a sale of shares and not a financial report, earnings release, or management discussion. Therefore, it fits best into the category of Capital/Financing Update (CAP), which covers updates on fundraising, financing activities, or capital structure changes.
2026-06-19 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a letter addressed to stock exchanges and the company's audit committee regarding disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. It declares that there has been no encumbrance made by the promoters or persons acting in concert during the financial year 2025-26. The content is a regulatory disclosure about shareholding and control, related to takeover regulations and promoter group actions. It is not an annual report, earnings release, financial statement, or voting result. The document fits the description of a Major Shareholding Notification because it relates to disclosures required under share acquisition and takeover rules, even though it indicates no new encumbrance. Therefore, the best classification is Major Shareholding Notification (MRQ). The length is short and it is a direct regulatory disclosure, so it is not a report publication or a general regulatory filing beyond the scope of shareholding notifications.
2026-06-12 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 90% confidence The document is an intimation letter under SEBI Regulation 47 sent to the BSE/NSE, stating that newspaper extracts of the audited standalone and consolidated financial results have been published and are enclosed. It does not itself contain the full financial statements but merely announces and attaches the publication of results (newspaper cuttings). Thus, by the “menu vs meal” rule it is an announcement of a report’s publication, fitting the Report Publication Announcement (RPA) category rather than the report itself.
2026-05-30 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.